# Downstream purification (Protein A capture, viral clearance, polishing)

Source: https://onco.cc/technologies/downstream-purification-chromatography/  
OnCo record `downstream-purification-chromatography` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

After hamster cells have grown an antibody drug, the antibody has to be fished out of a soup of cells, DNA and viruses and made pure enough to inject. Purification is where much of the cost and many of the bottlenecks of biologics sit.

## Summary

Downstream processing takes the harvested cell culture fluid from a CHO bioreactor and turns it into bulk drug substance. The harvest is clarified by centrifugation and depth filtration, captured on a Protein A affinity column that binds the antibody's Fc region and lets everything else through, held at low pH to inactivate enveloped viruses, polished on ion exchange and mixed-mode columns to strip host-cell proteins, DNA and aggregates, passed through a virus-retaining nanofilter, and concentrated and buffer-exchanged by ultrafiltration and diafiltration before sterile filtration. Regulators require validated viral clearance of several orders of magnitude across the steps, and every batch is tested for host-cell protein, DNA, aggregates, charge variants and glycan pattern.

Protein A resin is the single most expensive consumable in antibody manufacture and is supplied by a small number of makers (Cytiva, Merck KGaA's life science arm, Thermo Fisher, Purolite and Tosoh among them), and column and membrane capacity, not bioreactor volume, often sets how fast a plant can run as titres rise. Continuous and multi-column chromatography, membrane adsorbers and precipitation are the current efficiency frontier. Antibody-drug conjugates repeat parts of this chain after conjugation to remove free payload.

## Fields

- Kind: Technology
- Status: standard-of-care
- Last checked: 2026-09-17
- Tags: manufacturing-wave
- Principle: Sequential capture, viral inactivation and polishing steps exploit affinity, charge and size to reach injectable purity with validated viral safety.
- Since: 1990
- Strengths: Platform process reused across antibodies; Validated viral safety; Resins reusable for hundreds of cycles
- Limitations: Protein A resin cost and supplier concentration; Downstream capacity lags rising titres; Each new format (bispecific, ADC) needs process redevelopment

## Sources

- ICH Q5A: viral safety evaluation of biotechnology products: https://www.ich.org/page/quality-guidelines
- Wikipedia: https://en.wikipedia.org/wiki/Protein_A

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [ADC bioconjugation manufacturing (CDMOs)](https://onco.cc/technologies/adc-cdmo-manufacturing/), [Antibody manufacturing (CHO bioprocessing)](https://onco.cc/technologies/monoclonal-antibody-manufacturing/), [Biosimilar manufacturing and comparability](https://onco.cc/technologies/biosimilar-manufacturing/), [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Single-use bioprocessing systems](https://onco.cc/technologies/single-use-bioprocessing/), [Sterile fill-finish and lyophilisation](https://onco.cc/technologies/sterile-fill-finish/), [The ADC supply chain (antibody, payload-linker, conjugation, fill)](https://onco.cc/technologies/adc-supply-chain/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Rituximab](https://onco.cc/drugs/rituximab/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/)
- companies: [Boehringer Ingelheim BioXcellence](https://onco.cc/companies/boehringer-ingelheim-biox/), [Cytiva (Danaher)](https://onco.cc/companies/cytiva/), [FUJIFILM Diosynth Biotechnologies](https://onco.cc/companies/fujifilm-diosynth/), [Lonza](https://onco.cc/companies/lonza/), [Merck KGaA (EMD Serono)](https://onco.cc/companies/merck-kgaa/), [Samsung Biologics](https://onco.cc/companies/samsung-biologics/), [Sartorius](https://onco.cc/companies/sartorius/), [Thermo Fisher Scientific](https://onco.cc/companies/thermo-fisher/), [WuXi Biologics](https://onco.cc/companies/wuxi-biologics/)

---
JSON: https://onco.cc/api/v1/entities/downstream-purification-chromatography.json